Searchable abstracts of presentations at key conferences in endocrinology

ea0077p213 | Neuroendocrinology and Pituitary | SFEBES2021

The use of low dose tolvaptan for the treatment for hyponatraemia - a retrospective analysis of its efficacy and safety

Llewellyn David , Aylwin Simon

Aims: The lowest licensed dose of tolvaptan for treatment of hyponatraemia is 15 mg. There is little data on lower doses. Our study aimed to evaluate the safety of an initial dose of 7.5 mg tolvaptan.Methods: We retrospectively reviewed data from a London teaching hospital over a 6-year period. All adults administered a first dose of 7.5 mg tolvaptan were included. Three different timeframes were reviewed: 4-12, 12-18 and 18-30 hours. We analysed respons...